✨ Free AI Report
Oxford Biomedica plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Oxford Biomedica plc
Company Research

Oxford Biomedica plc: Business Overview, Financials & Competitive Analysis

Oxford Biomedica is a global quality and innovation-led cell and gene therapy CDMO specialising in viral vector therapies with 25+ years of expertise. The company operates through two segments: a high-growth CDMO plat...

Analyst-debate audio for Oxford Biomedica plc

AskCyborg analysts argue the bull and bear cases for Oxford Biomedica plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Strong CDMO growth with expanding commercial manufacturing capabilities, but improved profitability trajectory needed to justify...

Read the full analyst-debate transcript →
Industry Cell & Gene Therapy Contract Development and Manufacturing Organisation (CDMO)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Oxford Biomedica plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Oxford Biomedica plc Overview

Pro stress-test →

Oxford Biomedica is a global quality and innovation-led cell and gene therapy CDMO specialising in viral vector therapies with 25+ years of expertise. The company operates through two segments: a high-growth CDMO platform serving major pharmaceutical clients and early-stage product development. OXB now expects revenues of £220–240 million in 2026, with growth rising 25–30% annually through 2028.

Strategic Profile

Pro stress-test →

Oxford Biomedica is doubling down on its standalone strategy in viral vector contract manufacturing, pointing to strong demand, a robust pipeline and scalable capabilities. Under a new agreement with Bristol Myers Squibb, OXB is expected to commence commercial manufacturing in 2026 at facilities in Oxford, UK, and Durham, NC, US.

Competitive Landscape

Pro stress-test →

Oxford Biomedica is a UK-headquartered CDMO specialising in cell and gene therapy with focus on viral vector technologies including lentiviral, AAV and adenoviral systems. The company competes with specialized CDMOs in the rapidly growing cell and gene therapy sector, differentiated by its proprietary LentiVector platform and established manufacturing capabilities.

Industry Context

Oxford Biomedica plc operates in Cell & Gene Therapy Contract Development and Manufacturing Organisation (CDMO).

Key facts

Founded: 1996 · Headquarters: Oxford, United Kingdom · Revenue: £166-169 million (FY 2025)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Oxford Biomedica plc.

  • EQT has withdrawn its takeover offer after the board rejected four acquisition proposals, with the board concluding proposals undervalued the company.
  • Commercial manufacturing with Bristol Myers Squibb on BMS CAR-T programmes subject to regulatory approval is expected to commence in 2026.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Board unanimously rejected EQT's four acquisition proposals after concluding they undervalued the company
  • February 2026Expanded Bristol Myers Squibb commercial supply agreement for lentiviral vector manufacturing
  • +1 moreTrack every material event for Oxford Biomedica plc as it happens. Explore monitoring →
Get alerted when Oxford Biomedica plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

AAV/Lentiviral Vector ManufacturingGlobal CDMO competitor in viral vector manufacturing→Cell Therapy CDMO ServicesCell and gene therapy contract manufacturing→Viral Vector DevelopmentViral vector and cell therapy manufacturing partner→

Compare Oxford Biomedica plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Oxford Biomedica plc operates in Cell & Gene Therapy Contract Development and Manufacturing Organisation (CDMO). See how the rest of the sector scores on the Cyborg framework.

Browse Cell & Gene Therapy Contract Development and Manufacturing Organisation (CDMO) research →
NEW · MCP server

Ask your AI assistant about Oxford Biomedica plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Oxford Biomedica plc and its top competitor on Cyborg Score”
“What did Oxford Biomedica plc do this quarter?”
“Is Oxford Biomedica plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Oxford Biomedica plc do?+
Oxford Biomedica is a global quality and innovation-led cell and gene therapy CDMO specialising in viral vector therapies with 25+ years of expertise. The company operates through two segments: a high-growth CDMO plat...
What is Oxford Biomedica plc's Cyborg Score?+
Oxford Biomedica plc has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Oxford Biomedica plc's main competitors?+
Named competitors include AAV/Lentiviral Vector Manufacturing, Cell Therapy CDMO Services, Viral Vector Development. The full competitive landscape is in the AskCyborg report.
How can I get the full Oxford Biomedica plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Oxford Biomedica plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Oxford Biomedica plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.